Pages that link to "Q80601052"
Jump to navigation
Jump to search
The following pages link to Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France (Q80601052):
Displaying 14 items.
- Burden of allergic respiratory disease: a systematic review (Q28079329) (← links)
- Decision-making analysis for allergen immunotherapy versus nasal steroids in the treatment of nasal steroid-responsive allergic rhinitis (Q30415158) (← links)
- Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children (Q34070852) (← links)
- Specific immunotherapy by the sublingual route for respiratory allergy (Q34353492) (← links)
- Sublingual immunotherapy in children: facts and needs (Q34613104) (← links)
- Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses (Q36411170) (← links)
- Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults (Q36791729) (← links)
- Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis (Q37684339) (← links)
- The Health Economics of Allergen Immunotherapy (Q37870453) (← links)
- Immunotherapy – Traditional (Q37881279) (← links)
- Trends in Specific Immunotherapy for Allergic Rhinitis: A Survey of Chinese ENT Specialists (Q42716940) (← links)
- Chinese Guideline on allergen immunotherapy for allergic rhinitis (Q47149942) (← links)
- Sub-lingual immunotherapy: world allergy organization position paper 2009. (Q55527154) (← links)
- Health economics of allergen-specific immunotherapy in the United States (Q83143854) (← links)